Document:

Exhibit 4.12

    Exhibit
      4.12

     

    

      CONVERSION
        AGREEMENT

      

      This
        Agreement executed on March 8, 2006 is made by and between Cobalis Corp.,
        a
        Nevada corporation (the “Company”) with its principal place of business located
        at 2445 McCabe Way, Suite 150, Irvine CA 92614 and Vesna Petrovic (the
“Consultant”), with an address at 421 San Vicente Blvd., Santa Monica, CA
        90402.

      

      NOW
        THEREFORE, in consideration of the foregoing recitals and the covenants and
        obligations set forth below and for other good and valuable consideration,
        the
        receipt and sufficiency of which are hereby acknowledged, the Parties agree
        as
        follows:

      

      Consulting
        Fees Conversion:
        The
        Consultant has rendered his professional product, PreHistin, packaging design,
        production and print coordination services
        to the Company. The Consultant has submitted to the Company an invoice totaling
        $4,500 (four thousand five hundred dollars). The Parties hereby agree to
        convert
        $4,500 (four thousand five hundred dollars), the full amount of this obligation
        of the Company, into 3,000 (three thousand) fully-paid and non-assessable
        free
        trading shares, at the conversion rate of $1.50 per share, upon the execution
        of
        this Agreement. 

      

      The
        Company shall immediately issue an S-8 registration with the Securities and
        Exchange Commission in order to fulfill its obligation to the
        Consultant.

      

      IN
        WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
        date
        first written above.

       

      
         

        
          
            	The Company (Cobalis,
                    Corp.) 	 	 	The Consultant (Vesna
                    Petrovic)
	 	 	 	 
	/s/ Chaslav
                    Radovich	 	 	/s/ Vesna
                    Petrovic
	
                    
                      

                    

                    Chaslav Radovich

                    President/CEO

                  	 	 	
                    
Vesna
                    PetrovicExhibit 4.13

    Exhibit
      4.13

     

     

    

      Consulting
        Agreement

      

      between

      

      Lyndon
        E. Mansfield, MD and Cobalis Corp.

      

      This
        Agreement made this 8th
        day of
        November 2005, by and between Cobalis Corp., a Nevada corporation (CLSC)
        (hereinafter “Company”), located at 2445 McCabe Way, Ste. 150, Irvine CA 92614,
        and Lyndon E. Mansfield, MD (hereinafter “Consultant”) of 1901 Arizona, El Paso,
        TX, 79902.

      

      NOW,
        THEREFORE, in consideration of the foregoing premises, terms, covenants,
        and
        conditions hereinafter set forth, and other good and valuable consideration,
        the
        receipt and sufficiency of which are hereby acknowledged, the parties hereby
        agree as follows:

      

      RECITALS

      

      A. Company
        is a pharmaceutical company engaged in the business of researching, developing
        medications for allergic (atopic) diseases such as seasonal allergic rhinitis,
        asthma, migraine, and dermatitis. 

      

      B. Company
        desires to have services and responsibilities (hereinafter “Responsibilities”)
        provided by Consultant.

      

      C. Consultant
        is a medical doctor, board certified in allergy/immunology, who has extensive
        knowledge of allergic disease, clinical research, FDA, and pharmaceutical
        industry. 

      

      D. Consultant
        is willing to provide medical expertise in the capacity of Medical Advisor
        to
        the Company and to perform the following Responsibilities, on average about
        4-5
        working days per month.

      
        
           

        

        
          1

          
            

          

        

        
           

        

      

      Therefore,
        the parties agree as follows:

      

      1. DESCRIPTION
        OF SERVICES AND RESPONSIBILITIES.

      Dr.
        Mansfield’s Responsibilities include, but are not limited to:

      Development
        of protocols to be submitted to FDA.

      Developing
        an investigator’s manual for the phase 3 study.

      Reviewing
        the offers of CRO to provide support, to search out and /or develop methods
        which can decrease the costs of performing the monitoring and data
        capture.

      Reviewing
        and developing the methods for the NDA- IND submission for approval.

      Finding
        cost effective ways to complete studies.

      Designing
        phase 4 studies to expand the indications

      Serving
        as the scientific and clinical voice for the team.

      Serving
        as scientific and clinical spokesman for publicity.

      Serving
        as Medical Advisor for all clinical trials.

      Encouraging
        and selecting highly competent successful principal investigators for our
        trials. 

      To
        use my
        personal knowledge and relationship with these investigators.

      Making
        certain that our budgets are incentivized in a manner which provides the
        greatest value to the company in terms of time to complete
        projects.

      To
        represent company at investigators meeting as required medical writing and
        medical review as required.

      Be
        available for consultation with the rest of the team as required.

      Constantly
        review the old B12 literature as well as maintain the most updated information,
        including studies of immune related disorders, other than allergy, atopy
        or
        asthma. 

      Help
        with
        the development of a migraine study. Any actual work involving subjects on
        a
        migraine study will fall under a separate agreement. 

      Help
        with
        the development of a bioavailability study. Any actual work involving subjects
        on a bioavailability study will fall under a separate agreement. 

      

      

      2. COMPENSATION.

      In
        consideration for performing the above “Responsibilities”, Cobalis Corp. agrees
        to provide Dr. Mansfield with the following compensation (hereinafter
“Compensation”) beginning in October 1, 2005 and ending September 30,
        2006.

      

      2.1 A
        payment
        of two thousand five hundred US dollars ($2500) per month, payable on the
        1st
        day of
        each month. 

      

      2.2 One
        hundred thousand (100,000) warrants in Cobalis (CLSC) with a strike price
        of
        $1.75 and exercisable for seven (7) years of signing this Agreement.

      

      2.3 The
        ability to exercise Consultant’s options 12 months from the date of signing
        Agreement.

       

      
        
           

        

        
          2

          
            

          

        

        
           

        

      

      

      2.4 It
        is
        agreed to by both parties that if payment described in 2.1 above is missed
        to
        Mansfield on two (2) consecutive months, Dr. Mansfield will no longer required
        to continue with his Responsibilities until the monies due are paid, and
        that
        Dr. Mansfield can and will seek redress until resolution.

      

      2.5 The
        Company agrees to reimburse Consultant for reasonable travel expenses, subject
        to prior written approval, should the Consultant travel on behalf of the
        Company, for example to FDA, drug companies or study sites, such expenses
        to
        include airfare, hotel, car rental and meals. 

      

      2.6 Both
        parties agree that if the average time to perform the Responsibilities increases
        in an unforeseen way, Dr. Mansfield may request in writing additional payments
        to hire clinical support for the practice and for other Responsibilities,
        and
        that the Company will honor such reasonable requests.

      

      2.7 Thirty
        thousand (30,000) shares in Cobalis (CLSC) issued within thirty days of signing
        this Agreement. These 30,000 shares will have piggy-back rights on the next
        registration filed by Cobalis. 

      

      2.8 Twenty
        five thousand (25,000) shares in Cobalis (CLSC) issued within thirty days
        of
        signing this Agreement to satisfy all remaining monies and fees due Mansfield
        from the Agreement dated August 24, 2004. These 25,000 shares will have
        piggy-back rights on the next registration filed by Cobalis.

      

      

      3. RELATIONSHIP
        OF PARTIES.

      It
        is
        understood by the parties that Consultant is an independent contractor with
        respect to Company, and not an employee of Company. Company will not provide
        fringe benefits, including health insurance, paid vacation, or any other
        employee benefit. 

      

      4. EMPLOYEES.

      Consultant’s
        employees, if any, who perform services for Company under this Agreement
        shall
        also be bound by the provisions of this Agreement. Any such employees shall
        be
        employees of consultant only, and not employed by Cobalis Corp.

      

      5. ASSIGNMENT.

      Consultant’s
        obligations this Agreement may not be assigned or transferred to any other
        person or firm, or corporation without the prior written consent of
        Company.

      

      6. ENTIRE
        AGREEMENT.

      This
        Agreement contains the entire agreement of the parties and there are no promises
        or conditions in any other agreement whether oral or written. This Agreement
        supersedes any prior written or oral agreements between the parties. It is
        understood by both parties that the options and shares described in above
        are in
        addition to the all other options and shares already owned by or promised
        to
        Mansfield under previous agreements.

       

      
        
           

        

        
          3

          
            

          

        

        
           

        

      

      

      7. AMENDMENT.

      This
        Agreement may be modified or amended if the amendment is made in writing
        and
        signed by both parties. 

      

      8. SEVERABILITY.

      If
        any
        provision of this Agreement shall be held to be invalid or unenforceable
        for any
        reason, the remaining provisions shall continue to be valid and enforceable.
        If
        a court finds that any provision of this Agreement is invalid or unenforceable,
        but that by limiting such provision it would become valid and enforceable,
        then
        such provision shall be deemed to be written, construed, and enforced as
        so
        limited.

      

      9. APPLICABLE
        LAW.

      This
        Agreement shall be governed by the laws of the State of Nevada.

      

      10. TERMINATION.

      This
        Consulting Agreement can be terminated at any time with 60 days written notice
        by either party without statement of cause.

       

      
 

      Agreed
        to
        on November 8, 2005 by party receiving services and
        Responsibilities:

       

      
        	 	 	 	 
	/s/ Chas
                Radovich	 	 	 
	
                

                Chas
                  Radovich, CEO

                Cobalis
                  Corp.

              	 	 	
              

      

       

       

       

      Agreed
        to
        on November 8, 2005 by party providing services and
        Responsibilities:

       

      
        
          	 	 	 	 
	/s/ Lyndon
                  E. Mansfield, MD	 	 	 
	
                  

                  
                    Lyndon
                      E. Mansfield, MD

                  

                	 	 	
                

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]